Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of postoperative oral elemental nutritional supplement on skeletal muscle loss after gastrectomy for gastric cancer.
Nishikawa K, Kimura Y, Kishi K, Inoue K, Matsuyama J, Akamaru Y, Tamura S, Kawada J, Kawase T, Kawabata R, Fujiwara Y, Kanno H, Yamada T, Shimokawa T, Imamura H. Nishikawa K, et al. Among authors: akamaru y. Int J Clin Oncol. 2024 Mar;29(3):266-275. doi: 10.1007/s10147-023-02462-3. Epub 2024 Jan 16. Int J Clin Oncol. 2024. PMID: 38227091
Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial.
Tsujinaka T, Yamamoto K, Fujita J, Endo S, Kawada J, Nakahira S, Shimokawa T, Kobayashi S, Yamasaki M, Akamaru Y, Miyamoto A, Mizushima T, Shimizu J, Umeshita K, Ito T, Doki Y, Mori M; Clinical Study Group of Osaka University on Section of Risk Management. Tsujinaka T, et al. Among authors: akamaru y. Lancet. 2013 Sep 28;382(9898):1105-12. doi: 10.1016/S0140-6736(13)61780-8. Lancet. 2013. PMID: 24075050 Clinical Trial.
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Nishikawa K, et al. Among authors: akamaru y. Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18. Eur J Cancer. 2015. PMID: 25797356 Free article. Clinical Trial.
Risk factors for superficial incisional surgical site infection after gastrectomy: analysis of patients enrolled in a prospective randomized trial comparing skin closure methods.
Endo S, Tsujinaka T, Fujitani K, Fujita J, Tamura S, Yamasaki M, Kobayashi S, Akamaru Y, Mizushima T, Shimizu J, Umeshita K, Ito T, Mori M, Doki Y. Endo S, et al. Among authors: akamaru y. Gastric Cancer. 2016 Apr;19(2):639-644. doi: 10.1007/s10120-015-0494-z. Epub 2015 Apr 11. Gastric Cancer. 2016. PMID: 25862566 Clinical Trial.
Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial.
Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, Kimura Y, Tamura S, Kawabata R, Kawada J, Fujiwara Y, Kawase T, Fukui J, Takagi M, Takeno A, Shimokawa T. Imamura H, et al. Among authors: akamaru y. Ann Surg Oncol. 2016 Sep;23(9):2928-35. doi: 10.1245/s10434-016-5221-4. Epub 2016 Apr 15. Ann Surg Oncol. 2016. PMID: 27084538 Clinical Trial.
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial.
Nishikawa K, Murotani K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Hasegawa H, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Nishikawa K, et al. Among authors: akamaru y. Cancer Chemother Pharmacol. 2019 May;83(5):867-874. doi: 10.1007/s00280-019-03802-9. Epub 2019 Feb 26. Cancer Chemother Pharmacol. 2019. PMID: 30806758 Clinical Trial.
Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer.
Nishikawa K, Koizumi W, Tsuburaya A, Yamanaka T, Morita S, Fujitani K, Akamaru Y, Shimada K, Hosaka H, Nakayama N, Tsujinaka T, Sakamoto J. Nishikawa K, et al. Among authors: akamaru y. Gastric Cancer. 2020 Jan;23(1):160-167. doi: 10.1007/s10120-019-00990-4. Epub 2019 Jul 15. Gastric Cancer. 2020. PMID: 31309387
Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients (KSES002).
Kimura Y, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, Tamura S, Kawada J, Kawase T, Kawabata R, Fujiwara Y, Kanno H, Yamada T, Shimokawa T, Imamura H. Kimura Y, et al. Among authors: akamaru y. Ann Gastroenterol Surg. 2019 Oct 10;3(6):648-656. doi: 10.1002/ags3.12290. eCollection 2019 Nov. Ann Gastroenterol Surg. 2019. PMID: 31788653 Free PMC article.
A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Terazawa T, Matsuyama J, Goto M, Kawabata R, Endo S, Imano M, Fujita S, Akamaru Y, Taniguchi H, Tatsumi M, Lee SW, Kurisu Y, Kawakami H, Kurokawa Y, Shimokawa T, Sakai D, Kato T, Fujitani K, Satoh T. Terazawa T, et al. Among authors: akamaru y. Oncologist. 2020 Feb;25(2):119-e208. doi: 10.1634/theoncologist.2019-0601. Epub 2019 Sep 30. Oncologist. 2020. PMID: 32043772 Free PMC article. Clinical Trial.
81 results